Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Jan 22;28(4):1069-74. doi: 10.1016/j.vaccine.2009.10.113. Epub 2009 Nov 13.

DeltaznuADeltapurE Brucella abortus 2308 mutant as a live vaccine candidate.

Author information

  • 1Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717-3610, USA.


To create a new, safe brucellosis live vaccine, a double mutant strain was constructed from Brucella abortus 2308. Using the DeltaznuA B. abortus 2308 mutant, a second mutation was introduced by deleting purE gene. The DeltaznuA DeltapurE B. abortus 2308 strain was less capable of surviving in macrophages. When evaluated in vivo, it was cleared within 8 weeks (wks) from mice, causing significantly less inflammation than spleens obtained from wild-type B. abortus 2308-infected mice. Furthermore, two doses of DeltaznuA DeltapurE B. abortus 2308 conferred 0.79 log protection, similar to S19 as did a single dose of DeltaznuA B. abortus 2308. Thus, this study shows the DeltaznuA DeltapurE B. abortus 2308 strain to be a potential livestock vaccine candidate.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk